TargTex to present Tumour Eradication in Rodents from its Nanoformed Glioblastoma drug

[et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ custom_margin=”0px||||false|false” custom_padding=”0px||||false|false” global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ _module_preset=”default” custom_margin=”0px||||false|false” custom_padding=”0px||||false|false” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text admin_label=”Text” _builder_version=”4.17.6″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”]

Helsinki, Finland – Nanoform, an innovative nanoparticle medicine enabling company, together with TargTex, a European biotech company, will present highly promising in-vivo data, enabled by nanoformed drug product for the treatment of Glioblastoma. This data was generated for a planned Phase1/2a clinical trial, due to commence in early 2024.

The presentation at 10:00am EDT on 25 October at PODD Conference (Partnerships and Opportunities in Drug Delivery) in Boston, USA, will be given by Dr João Seixas, CEO, TargTex and Christian Jones, CCO, Nanoform. At this time the presentation including the released data will also be made available on Nanoform’s website.

News of Nanoform’s PoC* success and subsequent GMP Agreement with TargTex was published in February 2022. Since then, the companies have further collaborated in the optimization of a hydrogel formulation for implantation at the site of the resected tumor. This process demands very small particles to increase drug loading and improve release profile. Other technologies and approaches previously failed to deliver the necessary performance.

[/et_pb_text][et_pb_text admin_label=”Text” _builder_version=”4.17.6″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” custom_padding=”|||3%|false|false” border_width_left=”3px” border_color_left=”#335166″ global_colors_info=”{}”]

“In a space where unfortunately no significant advances were seen in the latest two decades, this novel approach provides hope for patients, and I wish we had started this collaboration with Nanoform sooner.” Dr João Seixas, CEO, TargTex

[/et_pb_text][et_pb_text _builder_version=”4.17.6″ _module_preset=”default” custom_padding=”|||3%|false|false” custom_css_before=”||||” custom_css_main_element=”||” border_color_all=”#335166″ border_width_left=”3px” global_colors_info=”{}”]

“We are thrilled that Nanoform’s platform technologies are able to help this highly promising medicine reach the clinic.” Prof. Edward Hæggström CEO, Nanoform

[/et_pb_text][et_pb_text admin_label=”Text” _builder_version=”4.17.6″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”]

 *PoC refers to Nanoform’s Proof of Concept study to assess nanoforming feasibility for an API

[/et_pb_text][/et_pb_column][/et_pb_row][et_pb_row _builder_version=”4.16″ _module_preset=”default” custom_padding=”10px|10px|10px|10px|false|false” border_width_all=”1px” border_color_all=”rgba(144,144,146,0.71)” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.17.6″ _module_preset=”default” global_colors_info=”{}”]

We’re delighted that Christian Jones,  the Chief Commercial Officer of Nanoform will be speaking on the “Go Green” session at Pharma Integrates on 17th November, 2022

[/et_pb_text][/et_pb_column][/et_pb_row][et_pb_row column_structure=”3_4,1_4″ use_custom_gutter=”on” gutter_width=”1″ make_equal=”on” _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”3_4″ _builder_version=”4.16″ _module_preset=”default” custom_padding=”10px||10px|10px|false|false” border_width_top=”1px” border_color_top=”rgba(144,144,146,0.71)” border_width_bottom=”1px” border_color_bottom=”rgba(144,144,146,0.71)” border_width_left=”1px” border_color_left=”rgba(144,144,146,0.71)” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”]

About Nanoform

Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to reduce attrition in clinical trials and enhance their molecules’ formulation performance through its nanoforming services. Nanoform’s unique technology provides novel opportunities in many value-enhancing drug delivery applications.

[/et_pb_text][/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.16″ _module_preset=”default” custom_padding=”10px|10px|10px||false|false” border_width_top=”1px” border_color_top=”rgba(144,144,146,0.71)” border_width_right=”1px” border_color_right=”rgba(144,144,146,0.71)” border_width_bottom=”1px” border_color_bottom=”rgba(144,144,146,0.71)” global_colors_info=”{}”][et_pb_image src=”https://lifescienceintegrates.com/wp-content/uploads/2021/03/Nanoform-2021.jpg” alt=”Nanoform-Logo” title_text=”Nanoform 3265″ _builder_version=”4.16″ _module_preset=”default” max_width=”90%” module_alignment=”center” global_colors_info=”{}”][/et_pb_image][/et_pb_column][/et_pb_row][/et_pb_section]

TargTex to present Tumour Eradication in Rodents from its Nanoformed Glioblastoma drug